Core Viewpoint - Recently, the company announced that it has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug Bupivacaine [2] Group 1 - The company is Zhejiang Anglikang Pharmaceutical Co., Ltd. [2] - The approved chemical raw material drug is Bupivacaine [2] - The announcement was made on the evening of November 17 [2]

Core Viewpoint - The stock of Shuoshi Biotechnology fell nearly 15% in the afternoon, with several other companies including Anglikang, Wanbangde, Kanglong Huacheng, Meidixi, Haoyuan Pharmaceutical, Jindike, and Jinshiyao also experiencing declines of over 5% [1] Company Performance - Shuoshi Biotechnology's stock decline of nearly 15% indicates significant market volatility [1] - Other companies in the sector, such as Anglikang and Wanbangde, also faced notable stock price drops, suggesting a broader trend affecting multiple firms [1] - The overall performance of the biotechnology sector appears to be under pressure, as indicated by the collective decline of several key players [1]

Core Viewpoint - Anglikon has received approval from the National Medical Products Administration for its chemical raw material drug, Bupivacaine, which meets the registration requirements for pharmaceuticals [1] Group 1: Company Information - Anglikon announced the receipt of the approval notice for the marketing application of Bupivacaine [1] - Bupivacaine is primarily used in clinical settings for local anesthesia and postoperative analgesia [1]

Core Viewpoint - The company, Anglikang (002940.SZ), has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Bupivacaine, which is primarily used for local anesthesia and postoperative analgesia [1] Group 1 - The drug Bupivacaine is a chemical raw material approved for marketing [1] - The approval is significant for clinical applications in local anesthesia and postoperative pain management [1]

Core Viewpoint - The company, Anglikang (002940.SZ), has received the approval notification from the National Medical Products Administration for the marketing application of the chemical raw material drug, Bupivacaine, which is primarily used for local anesthesia and postoperative analgesia [1] Group 1 - The drug Bupivacaine is a chemical raw material approved for marketing [1] - The approval is significant for the company's product portfolio in the anesthetic market [1] - Bupivacaine is clinically used for local anesthesia and postoperative pain relief [1]

Core Viewpoint - The company Anglikon (002940.SZ) has received approval from the National Medical Products Administration (NMPA) for the marketing application of its chemical raw material drug, Bupivacaine, which is primarily used for local anesthesia and postoperative analgesia [1] Group 1 - The approval notification was issued by the NMPA, indicating regulatory compliance and readiness for market entry [1] - Bupivacaine is a significant product in the field of anesthesia, enhancing the company's portfolio in the pharmaceutical industry [1]

证券代码：002940 证券简称：昂利康 公告编号：2025-088 浙江昂利康制药股份有限公司 关于获得化学原料药上市申请批准通知书的公告 申请内容：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。 二、产品基本情况 公司于 2023 年 12 月递交了布比卡因原料药的药品注册申请，于 2024 年 1 月获得受理，并于近日获得国家药监局批准。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，浙江昂利康制药股份有限公司（以下简称"公司"）收到国家药品监 督管理局（以下简称"国家药监局"）签发的《化学原料药上市申请批准通知书》。 现就相关情况公告如下： 一、批件基本信息 化学原料药名称：布比卡因 登记号：Y20230001273 生产企业名称：浙江昂利康制药股份有限公司 生产企业地址：绍兴嵊州市嵊州大道北 1000 号 布比卡因制剂临床上主要用于局部麻醉和术后镇痛。 三、对公司的影响 公司本次获得化学原料药布比卡因上市申请批准通知书，将进一步丰富公司 产品线，提升公司核心竞 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the chemical raw material drug Bupivacaine, enhancing its product line and core competitiveness [1] Summary by Relevant Categories Regulatory Approval - The company submitted the drug registration application for Bupivacaine in December 2023, which was accepted in January 2024, and has now received the approval notice [1] Product Information - Bupivacaine is primarily used for local anesthesia and postoperative analgesia, indicating its significance in clinical applications [1] Strategic Implications - The approval of Bupivacaine will further enrich the company's product portfolio, thereby improving its competitive edge in the market [1]

Core Insights - The company Anglikon (002940) has received approval from the National Medical Products Administration for the marketing application of Bupivacaine [1] Group 1 - Bupivacaine is primarily used in clinical settings for local anesthesia and postoperative analgesia [1]

Core Viewpoint - The company, Zhejiang Anglikang Pharmaceutical Co., Ltd., has announced its 2025 semi-annual profit distribution plan, which includes a cash dividend of 1.00 RMB per 10 shares for shareholders, excluding shares held in the company's repurchase account [2][6]. Group 1: Profit Distribution Plan - The total number of shares eligible for the profit distribution is 196,108,486, calculated by deducting 5,619,700 shares held in the repurchase account from the total share capital of 201,728,186 [2][6]. - The total cash dividend amount to be distributed is 19,610,848.60 RMB, calculated as 196,108,486 shares multiplied by 0.10 RMB per share [2][12]. - The cash dividend will be distributed on a basis of 1.00 RMB per 10 shares, with specific tax implications for different categories of shareholders [6][7]. Group 2: Shareholder Meeting and Approval - The profit distribution plan was approved at the company's first extraordinary general meeting held on October 16, 2025 [3][4]. - The distribution plan is consistent with the principles established during the shareholder meeting, ensuring that any changes in total share capital due to repurchases or other factors will be adjusted accordingly [4][5]. Group 3: Key Dates - The record date for the profit distribution is set for November 21, 2025, and the ex-dividend date is November 24, 2025 [8][9]. Group 4: Distribution Method - Cash dividends for A-share shareholders will be directly credited to their accounts through their respective securities companies on the ex-dividend date [10]. - The company will bear all legal responsibilities for any discrepancies in dividend distribution due to changes in shareholder accounts during the application period [11].